With all hands on deck at Vertex focused on the development of a crucial combo drug for cystic fibrosis, the Boston-based biotech has outlicensed an influenza drug to J&J in exchange for a $30 million upfront.

…read more

Source: J&J pays $30M to grab rights to Vertex program


0 No comments